Mirati Therapeutics, Inc.
(NASDAQ : MRTX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -4.90%58.570.0%$906.01m
AMGNAmgen, Inc. 1.22%258.241.3%$750.82m
GILDGilead Sciences, Inc. 0.38%76.351.0%$724.94m
REGNRegeneron Pharmaceuticals, Inc. 2.18%622.452.5%$659.43m
NVAXNovavax, Inc. 2.43%81.64102.0%$580.82m
BIIBBiogen, Inc. 0.13%265.121.6%$559.05m
VRTXVertex Pharmaceuticals, Inc. 1.68%291.101.9%$527.74m
ILMNIllumina, Inc. 1.24%373.103.5%$308.62m
ALXNAlexion Pharmaceuticals, Inc. -0.08%112.302.0%$228.46m
BMRNBioMarin Pharmaceutical, Inc. 0.75%126.784.3%$214.78m
SGENSeattle Genetics, Inc. 0.90%169.036.1%$202.30m
SRNESorrento Therapeutics, Inc. -1.15%6.851.8%$184.40m
SRPTSarepta Therapeutics, Inc. -1.77%162.7513.9%$167.23m
INCYIncyte Corp. 3.72%106.472.5%$163.35m
IMMUImmunomedics, Inc. 1.71%37.5411.0%$159.56m

Company Profile

Mirati Therapeutics, Inc. is a clinical-stage oncology company. The firm engages in developing a pipeline of oncology products to treat genetic, immunological and epigenetic drivers of cancer in subsets of cancer patients. Its clinical pipeline consists of glesatinib, sitravatinib and mocetinostat. The company was founded on December 13, 1995 and is headquartered in San Diego, CA.